Navigation Links
Wonder drug Dasatinib gives hopes to leukemia patients

The company Bristol-Myers Squibb Co at Boston told the press that the drug Dasatinib has led to reduction in the number of patients with Chronic myeloid leukemia (CML).//

This drug is very effective in the decreasing the leukemia cells from the bone marrow than the previously used drug Gleevec.

Chronic myeloid leukemia (CML) is usually presented in three different stages – Chronic stage, accelerated stage and the blast stage. Dasatinib was tried on all these stages of leukemia patients and the results were Out of the186 patients who are in the chronic stage, 45% of the patients attained complete elimination of the leukemia cells from the marrow.

Out of the 107 patients in the accelerated stage 31% who did not react to Gleevec responded positively to Dasatinib.

Out of the 74% in the blast stage (aggressive form) 29% of the patients attained complete elimination of the leukemia cells.

This is a boon to all those patients who do not react to Gleevec which is the treatment for Leukemia.

This drug will soon reach the markets by the end of the current year or the beginning of the next year.

Gleevec was a Swiss product and in 2001after approved by the Food and Drug Administration, made to the markets as the drug which attacks the BCR-ABL protein which results in the abnormal rise of leukocytes.

But with this drug some patients (20% of CML) did not respond to the drug or initially responded but later became resistant to the drug.

The mechanism of the drug action is that it attacks and prevents several proteins (BCR-ABL & SRC) in the same time. SRC is believed to help the leukemia cells to take the alternate pathway and become resistant to Gleevec, but Dasatinib prevents the action of SRC.

The toxicity level of Dasatinib is not more than Gleevec and it has to be brought in to the market for commercial use as the statistics show that in the current year the number of ch ronic CML patients to be 4600.

The company also relies on this drug to become the most famous cancer Drug Company and increase profit. It is estimated that this drug if put in circulation would yield six hundred million dollars to the company within a period of four years.

Related medicine news :

1. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
2. Wonder drug - could end in disaster
3. Have You Ever Wondered How We Perceive Different Sounds?
4. Soy Not Such A Wonder For Health?
5. Have You Ever Wondered Why Male And Female Voices Differ?
6. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
7. Femara: The Wonder Drug to Prevent Relapse of Breast Cancer.
8. Braces Work Wonders In Setting Crooked Teeth Right
9. Daughter Turns Saviour: Ailing Mother Provided Wonder Drug Herceptin, To Fight Cancer
10. Save Budhia - The Indian Wonder Kid
11. Wonder Drug For Weight Loss Launched In UK
Post Your Comments:

(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
Breaking Medicine Technology: